Prior CAR T-Cell Therapy Exposure May Impact Odronextamab Benefit in DLBCL

Odronextamab combinations may help elicit responses in DLBCL patients after CAR T-cell therapy failure. Duration of prior CAR T-cell therapy benefit predicts bispecific antibody response. Developing combination approaches with odronextamab aims to mitigate disease progression and elicit responses.